1. Home
  2. MQ vs AGIO Comparison

MQ vs AGIO Comparison

Compare MQ & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marqeta Inc.

MQ

Marqeta Inc.

HOLD

Current Price

$3.87

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.98

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MQ
AGIO
Founded
2010
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
MQ
AGIO
Price
$3.87
$33.98
Analyst Decision
Hold
Buy
Analyst Count
10
8
Target Price
$5.36
$38.88
AVG Volume (30 Days)
5.1M
898.0K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$624,884,000.00
$43,011,000.00
Revenue This Year
$16.89
$76.75
Revenue Next Year
$16.36
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
23.25
N/A
52 Week Low
$3.70
$22.24
52 Week High
$7.04
$46.00

Technical Indicators

Market Signals
Indicator
MQ
AGIO
Relative Strength Index (RSI) 48.25 69.45
Support Level $3.81 $26.71
Resistance Level $4.26 $36.07
Average True Range (ATR) 0.18 1.51
MACD 0.00 0.62
Stochastic Oscillator 30.47 92.86

Price Performance

Historical Comparison
MQ
AGIO

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: